CGRP antagonists: a new class of medications for the treatment of migraine

Professor Robert Cowan, Stanford University, discusses the CGRP antagonists, a new class of agents for the treatment of headache

Professor Robert Cowan sits on the scientific advisory boards of Amgen, Allergan/Abbvie, Biohaven, Teva; he receives author royalties from Penguin/Avery, Oxford Press, and Springer, and is a principle and co-founder of BonTriage, LLC.